TriangleNCT00949117 · REGISTRY CONDITION SEARCH
Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE2
- Status at capture
- TERMINATED
- Registry last update
- 2014-04-02
RATIONALE: Cyproheptadine hydrochloride may help improve appetite and lessen weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine hydrochloride is more effective with or without nutritional supplementation in improving weight and quality of life of young patients with weight loss caused by cancer or cancer treatment. PURPOSE: This randomized phase II trial is studying cyproheptadine hydrochloride to see how well it works when given together with or without nutritional supplementation in treating young patients with weight loss caused by cancer or cancer treatment.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Difference Between Measures of Weight at Baseline and at Week 24
Body Mass Index as Assessed at Baseline and 24 Weeks
Effect of Cyproheptadine Hydrochloride on Pre-albumin and Body Composition
Quality of Life as Assessed by Peds-FAACT Questionnaire at Baseline and at Weeks 4 and 24
Change in Weight for Age Z-score From Baseline Through 24 Weeks
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- INCLUSION CRITERIA: * ≥ 2 years and \< 18 years of age at the time of admission to the study * Meets one of the following criteria: * documented history of unintended weight loss \> 5% presumed secondary to cancer/treatment-related therapy within three months * BMI for age less than the 5th percentile * Diagnosed with cancer of any type * Concomitant cancer treatment (surgery, chemotherapy, radiotherapy) guidelines: * Patients who will complete concomitant cancer treatment during this study's 4-week intervention are not eligible * If patients are receiving concomitant cancer treatment, they should be scheduled to get at least another 4 weeks of treatment in order to reach the primary endpoint * If patients have already completed cancer treatment, they need to be enrolled within 8 weeks of completing therapy. * Predicted life expectancy of at least 6 months EXCLUSION CRITERIA: * Currently taking any of the study agents (cyproheptadine hydrochloride (CH), PediaSure, or Ensure) or have taken any of the study agents during the past 3 weeks * History of anorexia nervosa or bulimia * Initiation of other appetite enhancing agents including steroids prescribed for the intent of weight gain, i.e. Megace, is not allowed during this study * Children receiving steroids as part of their daily cancer treatment regimen are excluded from participation. However, intermittent steroid use in an antiemetic regimen or in other pulse steroid therapy is allowed during the study. * Use of other forms of nutrition therapies, e.g. total parenteral nutrition (TPN) or enteral tube feedings within 3 weeks of study entry or during study * Receiving monoamine oxidase (MAO) inhibitors, procarbazine, fluoxetine (SSRI), or paroxetine (SSRI) * Taking dronabinol (Marinol) or other appetite-stimulating medications during the past 3 weeks * Diagnosed with glaucoma, cystic fibrosis, inflammatory bowel disease or GI or genitourinary (GU) obstruction * Allergy to study agents * Hypersensitivity to specific milk proteins * Pregnant or lactating. Females of childbearing potential are required to use effective contraception while on study agent.
- healthy Volunteers
- false
- maximum Age
- 17 Years
- minimum Age
- 2 Years
- sex
- ALL
- std Ages
- CHILD
Treatment arms and interventions
- arm Groups
- description
- Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.
- intervention Names
- Drug: cyproheptadine hydrochloride
- label
- Arm I- cyproheptadine hydrochloride
- type
- EXPERIMENTAL
- description
- Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (\> 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.
- intervention Names
- Dietary Supplement: Ensure
- Dietary Supplement: PediaSure
- Drug: cyproheptadine hydrochloride
- label
- cyproheptadine HCl & PediaSure or Ensure
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- cyproheptadine HCl & PediaSure or Ensure
- description
- Given orally
- name
- Ensure
- other Names
- nutritional supplement drink
- type
- DIETARY_SUPPLEMENT
- arm Group Labels
- cyproheptadine HCl & PediaSure or Ensure
- description
- Given orally
- name
- PediaSure
- other Names
- nutritional supplement drink (pediatric)
- type
- DIETARY_SUPPLEMENT
- arm Group Labels
- Arm I- cyproheptadine hydrochloride
- cyproheptadine HCl & PediaSure or Ensure
- description
- Given orally
- name
- cyproheptadine hydrochloride
- other Names
- cyproheptadine HCl
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- SUPPORTIVE_CARE
Enrollment
- count
- 9
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Difference in measure of weight in kilograms of subject at baseline and at week 24 after continuing on study treatment for the entire 24 week period.
- measure
- Difference Between Measures of Weight at Baseline and at Week 24
- time Frame
- 24 weeks
- secondary Outcomes
- description
- Change in Body Mass Index (BMI) in subjects from Baseline visit to 24 week visit.
- measure
- Body Mass Index as Assessed at Baseline and 24 Weeks
- time Frame
- 24 weeks
- measure
- Effect of Cyproheptadine Hydrochloride on Pre-albumin and Body Composition
- time Frame
- 24 weeks
- measure
- Quality of Life as Assessed by Peds-FAACT Questionnaire at Baseline and at Weeks 4 and 24
- time Frame
- 24 weeks
- description
- Change in weight for age Z-score from Baseline through 24 weeks while on study treatment. Weight for age Z-score calculated using the Center for Disease Control and Prevention (CDC) weight-for-age Z score data tables.
- measure
- Change in Weight for Age Z-score From Baseline Through 24 Weeks
- time Frame
- Baseline and 24 weeks
Full study description
- brief Summary
- RATIONALE: Cyproheptadine hydrochloride may help improve appetite and lessen weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine hydrochloride is more effective with or without nutritional supplementation in improving weight and quality of life of young patients with weight loss caused by cancer or cancer treatment. PURPOSE: This randomized phase II trial is studying cyproheptadine hydrochloride to see how well it works when given together with or without nutritional supplementation in treating young patients with weight loss caused by cancer or cancer treatment.
- detailed Description
- OBJECTIVES: Primary * To compare the efficacy of an appetite stimulant, cyproheptadine hydrochloride, with vs without a nutritional supplement, PediaSure or Ensure, in improving weight and extending the duration of response in pediatric patients with cancer- or cancer treatment-related weight loss. Secondary * To compare patterns of body composition and weight change in patients treated with these regimens. * To compare the change in the relationship between pre-albumin (biomarker of malnutrition) and weight improvement from baseline to the completion of study treatment. * To compare the change in quality of life as measured by the Pediatric Functional Assessment of Anorexia and Cachexia Therapy (FAACT) questionnaire in patients treated with these regimens. OUTLINE: This is a multicenter study. Patients are stratified according to participating center and steroid use (yes vs no). Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity. * Arm II: Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (\> 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity. Patients undergo blood sample collection to assess pre-albumin levels at baseline and at weeks 4 and 24. Patients also undergo assessment of body composition, lean body mass, and percentage of body fat at baseline and at weeks 4 and 24 and assessment of weight and height at baseline and at weeks 4, 8, 12, 16, 20, and 24. Patients also complete a food diary twice a week during study treatment. Patients 7-17 years of age complete a quality-of-life questionnaire at baseline and at weeks 4 and 24.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-2512351a6b34147f5fc8
- requested nct id
- NCT00949117
- primary nct id
- NCT00949117
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- a4be8fb2a7db9247bdfed231ef84ae19b3babbe8d619ebf7403cceb730eae2d4
- payload sha256
- b7cfad535f00bbb0828b8a74ec8da8639f3322d3dab08f536f7ab04de09e2675
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-2512351a6b34147f5fc8
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT00949117
- occurrences
- context exact
- NCT00949117
- end
- 11
- exact text
- NCT00949117
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Childhood Myelodysplastic Neoplasms
- query disease state id
- ds-myelodysplastic-neoplasms-pediatric
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-myelodysplastic-neoplasms-000.json
- source file sha256
- a4be8fb2a7db9247bdfed231ef84ae19b3babbe8d619ebf7403cceb730eae2d4
- source json pointer
- /studies/11/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- b807722b741de6370e92ee1bf0588c39a75ea8cf858f45547a6a88044891e0a7
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-d26f8f1a146a7160f548
- requested nct id
- NCT00949117
- primary nct id
- NCT00949117
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- a6089e8b15d43633ec778b2a5c464ada1207289beea2ae90de3e4bbe04b32186
- payload sha256
- 427fec490bb75c1b4b64f6a473d24e65b51080f7ed02019ac501d6f8f61b1b01
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-d26f8f1a146a7160f548
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT00949117
- occurrences
- context exact
- NCT00949117
- end
- 11
- exact text
- NCT00949117
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Acute Undifferentiated Leukemia
- query disease state id
- ds-acute-undifferentiated-leukemia
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-acute-undifferentiated-leukemia-000.json
- source file sha256
- a6089e8b15d43633ec778b2a5c464ada1207289beea2ae90de3e4bbe04b32186
- source json pointer
- /studies/9/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- b807722b741de6370e92ee1bf0588c39a75ea8cf858f45547a6a88044891e0a7
Preserved source evidence · Not medical advice